Jim B. Farinholt
Fundador en DiaKine Therapeutics, Inc. .
Cargos activos de Jim B. Farinholt
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
DiaKine Therapeutics, Inc.
DiaKine Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology DiaKine Therapeutics, Inc. is a start-up biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. These drugs have the potential to restate the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease. Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes and represent a total available market opportunity of approximately $13 billion. The Company's lead compound, Lisofylline (LSF), has had an excellent safety profile in clinical trials to date. LSF works at the cellular level by improving the function of insulin producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself. This autoimmune action is the cause of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), which combined affect approximately three million people in the U.S. About three million people with type 2 diabetes use insulin due to diminished insulin production and an increasing resistance to insulin. A primary focus of DiaKine's research and development is on its next generation of orally bioavailable immune modulators which have an improved spectrum of action to LSF. Two such compounds, DT22669 and DT23552, have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications. | Director/Miembro de la Junta | - | - |
Fundador | 20/01/2010 | - |
Historial de carrera de Jim B. Farinholt
Antiguos cargos conocidos de Jim B. Farinholt.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Tall Oaks Capital Partners LLC
Tall Oaks Capital Partners LLC Investment ManagersFinance Tall Oaks Capital Partners LLC (Tall Oaks Capital) is a venture capital firm founded in 2000. The firm is headquartered in Charlottesville, Virginia. | Fundador | 01/01/2000 | 01/01/2012 |
Inversor de Capital Privado | 01/01/2000 | 01/01/2012 | |
PharmaNetics, Inc.
PharmaNetics, Inc. Medical SpecialtiesHealth Technology PharmaNetics, Inc. is a holding company incorporated as the parent company of Cardiovascular Diagnostics, Inc. Cardiovascular Diagnostics develops, manufactures and markets rapid turnaround diagnostics to assess blood clot formation and dissolution. Cardiovascular Diagnostics is also establishing itself in the emerging field of theranostics or rapid near-patient testing. PharmaNetics, Inc. was founded in 1998 and is located in Raleigh, NC | Director/Miembro de la Junta | - | 10/02/2009 |
The Virginia Biotechnology Research Park
The Virginia Biotechnology Research Park Real Estate DevelopmentFinance The Virginia Biotechnology Research Park operates a pharmaceutical and biotechnology corridor. The private company is based in Richmond, VA. Chandra Briggman has been the CEO of the company since 2020. | Director/Miembro de la Junta | 01/01/1996 | 01/01/1999 |
Galleher & Co.
Galleher & Co. Investment Banks/BrokersFinance Galleher & Co. provides brokerage and other financial services. | Director Ejecutivo | 01/01/1978 | 01/01/1988 |
Presidente | 01/01/1978 | 01/01/1988 | |
Nutriati, Inc.
Nutriati, Inc. BiotechnologyHealth Technology Nutriati, Inc. develops and formulates food products. It develops powders and flours that can be added to foods to boost the protein level or create gluten-free products. The company was founded by Richard Kelly and Michael Spinelli and is headquartered in Richmond, VA. | Director/Miembro de la Junta | - | - |
Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. Pharmaceuticals: MajorHealth Technology Nemucore Medical Innovations, Inc. is a clinical development company. It specializes in the development and commercialization of molecularly targeted therapeutics for the treatment of multi-drug resistant cancers with an emphasis on women's oncology. The company was founded by Timothy P. Coleman, Yuri Lvov, Vladimir Torchilin and Mansoor Amiji in 2008 and is headquartered in Wellesley, MA. | Director/Miembro de la Junta | - | - |
PluroGen Therapeutics, Inc.
PluroGen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology PluroGen Therapeutics LLC provides clinically advanced and advantaged burn, wound and skin care products. The firm also provides online ordering services. PluroGen Therapeutics was founded by George T. Rodeheaver and Adam J. Katz in February 2003 and is headquartered in Norristown, PA. | Director/Miembro de la Junta | - | - |
Corporate Officer/Principal | - | 01/08/2013 | |
Treasurer | 01/08/2013 | - | |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Fundador | - | - |
Corporate Officer/Principal | - | - | |
░░░░░ ░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Formación de Jim B. Farinholt.
Hampden-Sydney College | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 12 |
Operativa
Director/Board Member | 7 |
Founder | 3 |
Corporate Officer/Principal | 2 |
Sectorial
Health Technology | 8 |
Finance | 4 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
OWENS & MINOR, INC. | Health Technology |
Empresas privadas | 9 |
---|---|
PharmaNetics, Inc.
PharmaNetics, Inc. Medical SpecialtiesHealth Technology PharmaNetics, Inc. is a holding company incorporated as the parent company of Cardiovascular Diagnostics, Inc. Cardiovascular Diagnostics develops, manufactures and markets rapid turnaround diagnostics to assess blood clot formation and dissolution. Cardiovascular Diagnostics is also establishing itself in the emerging field of theranostics or rapid near-patient testing. PharmaNetics, Inc. was founded in 1998 and is located in Raleigh, NC | Health Technology |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
DiaKine Therapeutics, Inc.
DiaKine Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology DiaKine Therapeutics, Inc. is a start-up biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. These drugs have the potential to restate the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease. Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes and represent a total available market opportunity of approximately $13 billion. The Company's lead compound, Lisofylline (LSF), has had an excellent safety profile in clinical trials to date. LSF works at the cellular level by improving the function of insulin producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself. This autoimmune action is the cause of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), which combined affect approximately three million people in the U.S. About three million people with type 2 diabetes use insulin due to diminished insulin production and an increasing resistance to insulin. A primary focus of DiaKine's research and development is on its next generation of orally bioavailable immune modulators which have an improved spectrum of action to LSF. Two such compounds, DT22669 and DT23552, have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications. | Health Technology |
PluroGen Therapeutics, Inc.
PluroGen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology PluroGen Therapeutics LLC provides clinically advanced and advantaged burn, wound and skin care products. The firm also provides online ordering services. PluroGen Therapeutics was founded by George T. Rodeheaver and Adam J. Katz in February 2003 and is headquartered in Norristown, PA. | Health Technology |
Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. Pharmaceuticals: MajorHealth Technology Nemucore Medical Innovations, Inc. is a clinical development company. It specializes in the development and commercialization of molecularly targeted therapeutics for the treatment of multi-drug resistant cancers with an emphasis on women's oncology. The company was founded by Timothy P. Coleman, Yuri Lvov, Vladimir Torchilin and Mansoor Amiji in 2008 and is headquartered in Wellesley, MA. | Health Technology |
Nutriati, Inc.
Nutriati, Inc. BiotechnologyHealth Technology Nutriati, Inc. develops and formulates food products. It develops powders and flours that can be added to foods to boost the protein level or create gluten-free products. The company was founded by Richard Kelly and Michael Spinelli and is headquartered in Richmond, VA. | Health Technology |
Tall Oaks Capital Partners LLC
Tall Oaks Capital Partners LLC Investment ManagersFinance Tall Oaks Capital Partners LLC (Tall Oaks Capital) is a venture capital firm founded in 2000. The firm is headquartered in Charlottesville, Virginia. | Finance |
Galleher & Co.
Galleher & Co. Investment Banks/BrokersFinance Galleher & Co. provides brokerage and other financial services. | Finance |
The Virginia Biotechnology Research Park
The Virginia Biotechnology Research Park Real Estate DevelopmentFinance The Virginia Biotechnology Research Park operates a pharmaceutical and biotechnology corridor. The private company is based in Richmond, VA. Chandra Briggman has been the CEO of the company since 2020. | Finance |
- Bolsa de valores
- Insiders
- Jim B. Farinholt
- Experiencia